Clinical trial · Interventional
Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer
A Pilot Study of Rosiglitazone in Patients With Incurable Differentiated Thyroid Cancer
NCT00098852CI-TRIAL-00013330unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or metastatic thyroid cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| rosiglitazone maleate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Radioiodine uptake and thyroglobulin level at 6 months and 1 year
Secondary outcomes (1)
- measure
- Side effects of drug at 2 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of differentiated thyroid cancer * Locoregionally extensive and/or metastatic disease * Inoperable disease * Failed prior conventional therapy that included total/near-total thyroidectomy AND radioactive iodine I 131 ablation therapy * Elevated thyroglobulin (Tg) levels (\> 3 ng/mL on thyroid hormone OR \> 10 ng/mL off thyroid hormone) * Tg-antibody positive patients are eligible despite the Tg level * Radioactive iodine (RAI) scan showing no or therapeutically insignificant (\< 1%) RAI uptake after thyroid hormone withdrawal * Scan performed within the past 18 months PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Not specified Life expectancy * Not specified Hematopoietic * Hemoglobin ≥ 10 g/dL * WBC ≥ 3,000/mm\^3 * Platelet count ≥ 50,000/mm\^3 Hepatic * ALT ≤ 2 times upper limit of normal Renal * Creatinine ≤ 1.5 mg/dL Cardiovascular * No New York Heart Association class III or IV cardiac disease Other * Not pregnant * No nursing within the past 3 months * Negative pregnancy test * Fertile patients must use effective contraception * No allergy to thiazolidinediones * No other malignancy except basal cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * More than 3 months since prior chemotherapy Endocrine therapy * See Disease Characteristics * No concurrent levothyroxine Radiotherapy * See Disease Characteristics * No prior cumulative dose of radioiodine ≥ 800 mCi * Prior adjuvant or therapeutic external beam radiotherapy allowed Surgery * See Disease Characteristics
References
Publications (1)
- RESULTKebebew E, Reiff E, Greenspan FS, et al.: Rosiglitazone treatment induces radioiodine uptake in some patients with radioiodine-negative thyroglobulin-positive differentiated thyroid cancer. [Abstract] The Endocrine Society's 87th Annual Meeting, 4-7 June 2005, San Diego, CA. A-P3-573, 2005. Also available online. Last accessed February 21, 2006.